Bharat Parenterals Ltd
Bharat Parenterals Ltd Q3 FY24 Results & Presentation Highlights: Revenue ₹58.8 Cr, PAT ₹5.1 Cr
Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Bharat Parenterals Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Standalone Q3 FY 2024: - Revenue from operations: ₹58.8 crore (down 0.4% YoY) - Total operating revenue: ₹60.0 crore (down 1.5% YoY) - Consolidated Q3 FY 2024: - Revenue from operations: ₹59.8 crore (up 1.4% YoY) - Total operating revenue: ₹61.0 crore (up 0.2% YoY) - 9M FY 2024 vs 9M FY 2023 Performance: - Standalone revenue from operations up 12.9% - Consolidated revenue from operations up 13.5% - Volume or explicit outlook: - No explicit volume figures or forward-looking revenue/volume outlook stated in the presentation. Standalone Q3 FY 2024 vs Q3 FY 2023: - EBITDA: ₹10.4 crore, +10.6% YoY - EBITDA margin: 17.4% vs 15.5% YoY - PAT: ₹5.1 crore, +33.1% YoY - PAT margin: 8.5% vs 6.2% YoY - Consolidated Q3 F
From Bharat Parenterals Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Standalone Q3 FY 2024:
- Revenue from operations: ₹58.8 crore (down 0.4% YoY)
- Total operating revenue: ₹60.0 crore (down 1.5% YoY)
- Consolidated Q3 FY 2024:
- Revenue from operations: ₹59.8 crore (up 1.4% YoY)
- Total operating revenue: ₹61.0 crore (up 0.2% YoY)
- 9M FY 2024 vs 9M FY 2023 Performance:
- Standalone revenue from operations up 12.9%
- Consolidated revenue from operations up 13.5%
- Volume or explicit outlook:
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Vadodara manufacturing facility spans ~28,500 sq. mt land with ~14,300 sq. mt built-up area and ~4,300 sq. mt production area. It has infrastructure for future expansion including specialty products like lyophilized, pre-filled syringes, and complex emulsions. (Page 14)
- Commissioning of two new EU GMP-compliant blocks is underway to enable access to several APAC geographies; inspection and compliance completed, awaiting approval. (Page 15)
- Uganda Ministry of Health approval for existing blocks is being acquired; plans to obtain regulatory approvals from Ethiopia and Tanzania are underway. (Page 15)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY24)
Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY24 investor presentation — and how it ranks against
- NGL Fine Chem Ltd (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key investor presentation takeaways from NGL Fine
- Anuh Pharma Ltd (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key investor presentation takeaways from Anuh Pharma Ltd's Q3 FY24 investor pres
- Themis Medicare Ltd (Q3 FY24)
82.51 Cr, down 7.06% year-on-year from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY24 investor presentation — and how it ranks again
Frequently Asked Questions
What were Bharat Parenterals Ltd Q3 FY24 results?
Standalone Q3 FY 2024: - Revenue from operations: ₹58.8 crore (down 0.4% YoY) - Total operating revenue: ₹60.0 crore (down 1.5% YoY) - Consolidated Q3 FY 2024: - Revenue from operations: ₹59.8 crore (up 1.4% YoY) - Total operating revenue: ₹61.0 crore (up 0.2% YoY) - 9M FY 2024 vs 9M FY 2023 Performance: - Standalone revenue from operations up 12.9% - Consolidated revenue from operations up 13.5% - Volume or explicit outlook: - No explicit volume figures or forward-looking revenue/volume outlook stated in the presentation. Standalone Q3 FY 2024 vs Q3 FY 2023: - EBITDA: ₹10.4 crore, +10.6% YoY - EBITDA margin: 17.4% vs 15.5% YoY - PAT: ₹5.1 crore, +33.1% YoY - PAT margin: 8.5% vs 6.2% YoY - Consolidated Q3 F
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
The Vadodara manufacturing facility spans ~28,500 sq.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.